Aventis Gains Expedited Review, March Panel For HIV-Indicated Dermal Filler
This article was originally published in The Gray Sheet
Executive Summary
Expedited review of Aventis/Dermik Laboratories' Sculptra dermal filler to treat facial lipoatrophy in HIV-positive patients will precede a planned U.S. wrinkle indication, the firm says
You may also be interested in...
Aventis/Dermik’s Facial Repair Device Gets Compassionate Panel Nod
FDA should actively restrict access to Aventis/Dermik Labs' Sculptra injectable facial restoration agent to patients with HIV-related lipoatrophy, according to FDA's General & Plastic Surgery Devices Panel
Aventis/Dermik’s Facial Repair Device Gets Compassionate Panel Nod
FDA should actively restrict access to Aventis/Dermik Labs' Sculptra injectable facial restoration agent to patients with HIV-related lipoatrophy, according to FDA's General & Plastic Surgery Devices Panel
EU Tissue Directive Tackles TSE Fears; Avian Product Oversight May Grow
The European Commission may curtail approvals of animal-derived materials that have good synthetic alternatives, according to Paul Brooks, assistant VP-product services for BSI, Inc